Evacetrapib
Experimental drug for cardiovascular disease
Evacetrapib is a cholesterylester transfer protein (CETP) inhibitor that was being developed for the treatment of cardiovascular disease. CETP inhibitors are a class of drugs that aim to increase levels of high-density lipoprotein (HDL) cholesterol while reducing levels of low-density lipoprotein (LDL) cholesterol.
Mechanism of Action[edit | edit source]
Evacetrapib works by inhibiting the activity of CETP, a protein that facilitates the transfer of cholesterol esters from HDL to other lipoproteins such as LDL and very-low-density lipoprotein (VLDL). By inhibiting CETP, evacetrapib increases HDL cholesterol levels and decreases LDL cholesterol levels, which is believed to reduce the risk of atherosclerosis and subsequent cardiovascular events.
Clinical Development[edit | edit source]
Evacetrapib was developed by Eli Lilly and Company. It underwent several phases of clinical trials to evaluate its efficacy and safety in patients with cardiovascular disease. Despite showing promising results in early trials, a large Phase III clinical trial known as ACCELERATE was terminated in October 2015. The trial was stopped because evacetrapib did not demonstrate a significant reduction in major adverse cardiovascular events compared to placebo, despite substantial increases in HDL cholesterol and reductions in LDL cholesterol.
Pharmacokinetics[edit | edit source]
The pharmacokinetics of evacetrapib involve its absorption, distribution, metabolism, and excretion. The drug is administered orally and has a half-life that supports once-daily dosing. It is metabolized primarily in the liver and excreted through both renal and fecal pathways.
Side Effects[edit | edit source]
Common side effects observed in clinical trials included hypertension, gastrointestinal disturbances, and nasopharyngitis. The safety profile of evacetrapib was considered acceptable, but its lack of efficacy in reducing cardiovascular events led to the discontinuation of its development.
Related Pages[edit | edit source]
- Cholesterylester transfer protein
- High-density lipoprotein
- Low-density lipoprotein
- Atherosclerosis
- Eli Lilly and Company
- Cardiovascular disease
See Also[edit | edit source]
References[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
